Barrier posts Phase II results for antifungal drug

Barrier Therapeutics is reporting positive results from an ongoing Phase IIa study of pramiconazole, an oral antifungal treatment for patients with nail fungus. Patients enrolled in the study have shown a marked clinical improvement in total signs and symptoms of onychomycosis after 16 weeks of study. Full results from the study will be presented at a future scientific meeting. Pramiconazole may also be effective for a variety of other diseases, include tinea pedis (athlete's foot), tinea corporis (ring worm), tinea cruris, tinea versicolor, vaginal candidiasis and seborrheic dermatitis.

- take a look at Barrier's release

Related Articles:
Barrier reports positive data. Report
Barrier dermatitis treatment rejected by FDA. Report